Abstract
As a part of an ongoing effort to find alternate chemotherapeutic agents for hepatocellular carcinoma, we herein, report the design and synthesis of two novel compounds targeting histone deacetylase (HDAC) with 2,4-thiazolidinedione as zinc chelating group. Further, we demonstrate that these compounds show cytotoxicity that parallels their ability to inhibit HDACs activity in human liver cancer cell line HepG2. The findings obtained in this study indicate that 2,4-thiazolidinedione group may be utilized successfully to inhibit HDAC activity with future potential for lead optimization by chemical derivatization of active compound, N-(6-(2,4-dioxothiazolidin-3- yl)hexyl) benzenesulfonamide.
Graphical abstract
Similar content being viewed by others
References
Aoki K, Aikawa K, Kawakami M (2003) Benzimidazole compounds and drugs containing the same. US Patent US6593323B1, July 15, 2003
Avila MA, Berasain C, Sangro B, Prieto J (2006) New therapies for hepatocellular carcinoma. Oncogene 25:3866–3884
Carew JS, Giles FJ, Nawrocki ST (2008) Histone deacetylase inhibitors: mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 269:7–17
Dickinson J, Fowler SJ (2002) Quantification of proteins on western blots using ECL. In: Walker JM (ed) The protein protocols handbook, 2nd edn. Humana Press, Totowa, NJ, pp 429–438
Finnin MS, Donigian JR, Cohen A, Richon VM, Rifkind RA, Marks PA, Breslow R, Pavletich NP (1999) Structures of histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature 401:188–193
Joshi UJ, Shah FH, Tikhele SH (2006) Homology model of the human 5-HT1A receptor using the crystal structure of bovine rhodopsin. Internet Electron J Mol Des 5:403–415
Khare SP, Khade B, Gupta S (2009) Mass spectrometry-compatible silver staining of histones resolved on acid-urea-triton PAGE. Proteomics 9(9):2589–2592
Lai JP, Yu C, Moser CD, Adreca I, Han T, Garvey TD, Murphy LM, Garrity-Park MM, Shridhar V, Adjei AA, Roberts LR (2006) SULF1 inhibits tumor growth and potentiates the effects of histone deacetylase inhibitors in hepatocellular carcinoma. Gastroenterology 130:2130–2144
Mai A, Silvio M, Rotili D, Cerbara H, Valente S, Pezzi R, Simeoni S, Ragno R (2005) Histone deacetylation in epigenetics: an attractive target for anticancer therapy. Med Res Rev 25(3):261–309
Marin JGJ, Castano B, Martinez-Becerra P, Rosales R, Monte MJ (2008) Chemotherapy in the treatment of primary liver tumors. Cancer Therapy 6:711–728
Miller TA, Witter DJ, Belvedere S (2003) Histone deacetylase inhibitors. J Med Chem 46(24):5097–5116
Mold DE, Weingart J, Assaraf J, Lubahn DB, Kelner DN, Shaw BR, McCarthy KS Sr (1983) Silver staining of histones in triton-acid-urea gels. Anal Biochem 135:44–47
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63
Paris M, Porcelloni M, Binaschi M, Fattori D (2008) Histone deacetylase inhibitors: from bench to clinic. J Med Chem 51(6):1505–1529
Rikimaru T, Taketomi A, Yamashita Y, Shirabe K, Hamatsu T, Shimada M, Maehara Y (2007) Clinical significance of histone deacetylase 1 expression in patients with hepatocellular carcinoma. Oncology 72:69–74
Roberts LR, Gores GJ (2005) Hepatocellular carcinoma: molecular pathways and new therapeutic targets. Semin Liver Dis 25(2):212–225
Venturelli S, Armeanu S, Pathil A, Hsieh CJ, Weiss TS, Vonthen R, Wehrmann M, Gregor M, Lauer UM, Bitzer M (2007) Epigenetic combination therapy as a tumor-selective treatment approach for hepatocellular cancer. Cancer 109(10):2132–2141
Walkinshaw DR, Yang XJ (2008) Histone deacetylase inhibitors as novel anticancer agents. Curr Oncol 15(5):70–76
Warmus JS, Dilley GJ, Meyers AI (1993) A modified procedure for the preparation of 2,5-dihydropyrrole (3-pyrroline). J Org Chem 58:270–271
Waterborg JH (2002) Acid-urea-triton polyacrylamide gel electrophoresis of histones. In: Walker JM (ed) The protein protocols handbook, 2nd edn. Humana Press, Totowa, NJ, pp 113–124
Yamashita Y, Shimada M, Harimoto N, Rikimaru T, Shirabe K, Tanaka S, Sugimachi K (2003) Histone deacetylase inhibitor trichostatin A induces cell-cycle arrest/apoptosis and hepatocyte differentiation in human hepatoma cells. Int J Cancer 103:572–576
Acknowledgments
Dr C. S. Ramaa thanks Board of Research in Nuclear Sciences (BRNS), BARC, Mumbai, India (Sanction Number: 2006/37/41/BRNS) for financial support. Ms. Rhea Mohan is grateful to Board of Research in Nuclear Sciences (BRNS) for providing fellowship. We thank Dr. V. J. Kadam, Principal, Bharati Vidyapeeth’s College of Pharmacy, Navi Mumbai for providing support for the ongoing project. The authors would also like to express their gratitude to Mr. Bharat S. Khade, Scientific Assistant ‘D’, ACTREC, for technical support during the tenure of this work.
Conflict of interest
Authors have no conflict of interest regarding the work reported in this manuscript.
Author information
Authors and Affiliations
Corresponding authors
Rights and permissions
About this article
Cite this article
Mohan, R., Sharma, A.K., Gupta, S. et al. Design, synthesis, and biological evaluation of novel 2,4-thiazolidinedione derivatives as histone deacetylase inhibitors targeting liver cancer cell line. Med Chem Res 21, 1156–1165 (2012). https://doi.org/10.1007/s00044-011-9623-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00044-011-9623-3